Header Logo

Connection

Shabir Madhi to Antibodies, Bacterial

Back to Details
This is a "connection" page, showing publications Shabir Madhi has written about Antibodies, Bacterial.
Shabir Madhi
Connection Strength
11,689
Antibodies, Bacterial
  1. Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months of age: a randomized controlled study. Expert Rev Vaccines. 2025 Dec; 24(1):121-127.
    View in: PubMed
    Score: 0,883
  2. Infant serotype specific anti-capsular immunoglobulin G antibody and risk of invasive group B Streptococcal disease. Vaccine. 2021 11 16; 39(47):6813-6816.
    View in: PubMed
    Score: 0,704
  3. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Hum Vaccin Immunother. 2019; 15(3):658-668.
    View in: PubMed
    Score: 0,583
  4. Association between antibodies against group B Streptococcus surface proteins and recto-vaginal colonisation during pregnancy. Sci Rep. 2017 11 28; 7(1):16454.
    View in: PubMed
    Score: 0,537
  5. Antibody Kinetics and Response to Routine Vaccinations in Infants Born to Women Who Received an Investigational Trivalent Group B Streptococcus Polysaccharide CRM197-Conjugate Vaccine During Pregnancy. Clin Infect Dis. 2017 Nov 13; 65(11):1897-1904.
    View in: PubMed
    Score: 0,536
  6. Reduced Transplacental Transfer of Group B Streptococcus Surface Protein Antibodies in HIV-infected Mother-Newborn Dyads. J Infect Dis. 2017 02 01; 215(3):415-419.
    View in: PubMed
    Score: 0,507
  7. Natural acquired group B Streptococcus capsular polysaccharide and surface protein antibodies in HIV-infected and HIV-uninfected children. Vaccine. 2016 10 17; 34(44):5217-5224.
    View in: PubMed
    Score: 0,495
  8. Group B Streptococcus: developing a correlate of protection for a vaccine against neonatal infections. Curr Opin Infect Dis. 2016 06; 29(3):262-7.
    View in: PubMed
    Score: 0,484
  9. Correlates of protection of serotype-specific capsular antibody and invasive Group B Streptococcus disease in South African infants. Vaccine. 2015 Nov 27; 33(48):6793-9.
    View in: PubMed
    Score: 0,464
  10. Association between maternal Group B Streptococcus surface-protein antibody concentrations and invasive disease in their infants. Expert Rev Vaccines. 2015; 14(12):1651-60.
    View in: PubMed
    Score: 0,461
  11. HIV-1 Is Associated With Lower Group B Streptococcus Capsular and Surface-Protein IgG Antibody Levels and Reduced Transplacental Antibody Transfer in Pregnant Women. J Infect Dis. 2015 Aug 01; 212(3):453-62.
    View in: PubMed
    Score: 0,442
  12. Review on the association of Group B Streptococcus capsular antibody and protection against invasive disease in infants. Expert Rev Vaccines. 2015 Jan; 14(1):135-49.
    View in: PubMed
    Score: 0,431
  13. Effect of HIV-1 exposure and antiretroviral treatment strategies in HIV-infected children on immunogenicity of vaccines during infancy. AIDS. 2014 Feb 20; 28(4):531-41.
    View in: PubMed
    Score: 0,414
  14. Immunogenicity of seven-valent pneumococcal conjugate vaccine administered at 6, 14 and 40 weeks of age in South African infants. PLoS One. 2013; 8(8):e72794.
    View in: PubMed
    Score: 0,400
  15. Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infants. Vaccine. 2013 Jan 21; 31(5):777-83.
    View in: PubMed
    Score: 0,381
  16. Inferior quantitative and qualitative immune responses to pneumococcal conjugate vaccine in infants with nasopharyngeal colonization by Streptococcus pneumoniae during the primary series of immunization. Vaccine. 2011 Sep 16; 29(40):6994-7001.
    View in: PubMed
    Score: 0,346
  17. Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. J Infect Dis. 2010 Aug 15; 202(3):355-61.
    View in: PubMed
    Score: 0,324
  18. Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination. J Infect Dis. 2009 Apr 15; 199(8):1168-76.
    View in: PubMed
    Score: 0,295
  19. Impact of nutritional status on vaccine-induced immunity in children living in South Africa: Investigating the B-cell repertoire and metabolic hormones. Vaccine. 2024 May 22; 42(14):3337-3345.
    View in: PubMed
    Score: 0,209
  20. Immunogenicity of tetanus, diphtheria and acellular pertussis vaccination among pregnant women living with and without HIV. AIDS. 2023 12 01; 37(15):2305-2310.
    View in: PubMed
    Score: 0,201
  21. Potential for Maternally Administered Vaccine for Infant Group B Streptococcus. N Engl J Med. 2023 Jul 20; 389(3):215-227.
    View in: PubMed
    Score: 0,199
  22. Single priming and booster dose of ten-valent and 13-valent pneumococcal conjugate vaccines and Streptococcus pneumoniae colonisation in children in South Africa: a single-centre, open-label, randomised trial. Lancet Child Adolesc Health. 2023 05; 7(5):326-335.
    View in: PubMed
    Score: 0,194
  23. Association of Group B Streptococcus (GBS) Serum Serotype-Specific Anticapsular Immunoglobulin G Concentration and Risk Reduction for Invasive GBS Disease in South African Infants: An Observational Birth-Cohort, Matched Case-Control Study. Clin Infect Dis. 2021 09 07; 73(5):e1170-e1180.
    View in: PubMed
    Score: 0,174
  24. Effect of cytomegalovirus infection on humoral immune responses to select vaccines administered during infancy. Vaccine. 2021 08 09; 39(34):4793-4799.
    View in: PubMed
    Score: 0,173
  25. Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial. Lancet Infect Dis. 2020 12; 20(12):1426-1436.
    View in: PubMed
    Score: 0,162
  26. The Association Between Breast Milk Group B Streptococcal Capsular Antibody Levels and Late-onset Disease in Young Infants. Clin Infect Dis. 2020 03 03; 70(6):1110-1114.
    View in: PubMed
    Score: 0,157
  27. Effect of HIV-exposure and timing of antiretroviral treatment initiation in children living with HIV on antibody persistence and memory responses to Haemophilus influenzae type b and pneumococcal polysaccharide-protein conjugate vaccines. Vaccine. 2020 03 10; 38(12):2651-2659.
    View in: PubMed
    Score: 0,157
  28. Serocorrelates of protection against infant group B streptococcus disease. Lancet Infect Dis. 2019 05; 19(5):e162-e171.
    View in: PubMed
    Score: 0,145
  29. Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status. Medicine (Baltimore). 2017 Jan; 96(2):e5881.
    View in: PubMed
    Score: 0,126
  30. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial. Lancet Infect Dis. 2016 08; 16(8):923-34.
    View in: PubMed
    Score: 0,120
  31. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination. AIDS. 2015 Jul 17; 29(11):1345-54.
    View in: PubMed
    Score: 0,114
  32. Natural acquired humoral immunity against serotype-specific group B Streptococcus rectovaginal colonization acquisition in pregnant women. Clin Microbiol Infect. 2015 Jun; 21(6):568.e13-21.
    View in: PubMed
    Score: 0,111
  33. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatr Infect Dis J. 2013 Aug; 32(8):889-97.
    View in: PubMed
    Score: 0,099
  34. Association of Streptococcus pneumoniae common protein antigen (CPA) antibodies and pneumococcal nasopharyngeal colonization in HIV-infected and HIV-uninfected African children. Vaccine. 2013 Sep 13; 31(40):4421-7.
    View in: PubMed
    Score: 0,099
  35. Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatr Infect Dis J. 2011 Apr; 30(4):e68-74.
    View in: PubMed
    Score: 0,085
  36. Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines. Clin Vaccine Immunol. 2010 Jan; 17(1):134-42.
    View in: PubMed
    Score: 0,077
  37. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine. 2007 May 10; 25(19):3816-26.
    View in: PubMed
    Score: 0,064
  38. Immunogenicity and effectiveness of Haemophilus influenzae type b conjugate vaccine in HIV infected and uninfected African children. Vaccine. 2005 Dec 01; 23(48-49):5517-25.
    View in: PubMed
    Score: 0,057
  39. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J. 2005 May; 24(5):410-6.
    View in: PubMed
    Score: 0,056
  40. A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV. AIDS. 2023 07 01; 37(8):1227-1237.
    View in: PubMed
    Score: 0,048
  41. Immunogenicity and safety of a hexavalent pediatric vaccine in HIV-exposed infected and uninfected infants in Republic of South Africa. Hum Vaccin Immunother. 2021 06 03; 17(6):1770-1778.
    View in: PubMed
    Score: 0,041
  42. Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial. Lancet HIV. 2020 02; 7(2):e91-e103.
    View in: PubMed
    Score: 0,039
  43. Maternal immunization against Group B streptococcus: World Health Organization research and development technological roadmap and preferred product characteristics. Vaccine. 2019 11 28; 37(50):7391-7393.
    View in: PubMed
    Score: 0,034
  44. Immunogenicity of 13-valent pneumococcal conjugate vaccine among children with underlying medical conditions. Vaccine. 2017 08 03; 35(34):4321-4329.
    View in: PubMed
    Score: 0,033
  45. Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial. Lancet Infect Dis. 2016 May; 16(5):546-555.
    View in: PubMed
    Score: 0,030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.